Ken Griffin Verona Pharma PLC Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 140,100 shares of VRNA stock, worth $5.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140,100
Previous 17,700
691.53%
Holding current value
$5.27 Million
Previous $284,000
613.03%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VRNA
# of Institutions
150Shares Held
67.5MCall Options Held
495KPut Options Held
486K-
Ra Capital Management, L.P. Boston, MA7.63MShares$287 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$210 Million7.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$150 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$133 Million7.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.31MShares$125 Million2.82% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.29B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...